Pfizer Inc said on Tuesday it is reducing its U.S. sales staff as it expects doctors and other healthcare providers to want fewer face-to-face interactions with sales people after the COVID-19 pandemic ends, Trend reports citing Reuters.
The move comes as the company is expected to announce more than $80 billion in revenue in 2021 on strong sales of the COVID-19 vaccine it developed with Germany's BioNTech SE. That would be record sales for a pharmaceutical company, according to Pfizer Chief Executive Albert Bourla.
"We are evolving into a more focused and innovative biopharma company, and evolving the way we engage with healthcare professionals in an increasingly digital world," the company said in a statement.
"There will be some changes to our workforce to ensure we have the right expertise and resources in place to meet our evolving needs."
The company did not specify how many sales jobs it was cutting.